INVIVYD INC (IVVD)
Health Care · Biotechnology · NASDAQ
Invivyd is a clinical-stage biopharma company developing monoclonal antibody therapies designed to provide continuous protection against evolving viral threats like COVID-19, RSV, and measles.
What INVIVYD INC does
Invivyd is a biopharmaceutical company focused on the discovery, development, and commercialization of monoclonal antibody (mAb) therapies for the prevention and treatment of serious viral infectious diseases. Its primary focus is on SARS-CoV-2 (COVID-19), with its authorized product PEMGARDA being used for pre-exposure prophylaxis in immunocompromised individuals. The company is actively developing a pipeline of next-generation mAb candidates, including VYD2311 for COVID-19, as well as candidates for RSV and measles.
Recent developments
The company announced in July 2026 that the EUA for its only commercial product, PEMGARDA, will terminate on June 29, 2027. In August 2026, the company reported Q2 revenue growth and highlighted the completion of enrollment for its pivotal VYD2311 clinical trials, with top-line data expected in late Q3 2026.
From INVIVYD INC's filing of 2026-08-13.
Themes: COVID-19 therapeutics, monoclonal antibodies, RSV prophylaxis, Long COVID research, immunocompromised care
Fundamentals
- Price$0.7004 as of 2026-10-08 close
- Market cap$206M as of 2026-07-30 (share count; price 2026-10-08)
- 1-year return-57.3% 2025-10-08 close $1.64 → 2026-10-08 close $0.7004
- P/En/a negative earnings
- Net margin-98.2% FY2025, SEC XBRL
- ROE-21.7% FY2025, SEC XBRL
- Debt / equity0.00 as of 2026-09-02
- Revenue growth (YoY)+52.3% as of 2026-09-02
- Beta1.63 as of 2026-09-02
- Last reported earnings2026-08-13 SEC EDGAR Form 8-K (Item 2.02)
How IVVD compares in its sector
- net profit marginmiddle range 430 covered Health Care peers, as of 2026-09-02
- operating marginmiddle range 417 covered Health Care peers, as of 2026-09-02
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-02
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How INVIVYD INC looks technically
INVIVYD INC (IVVD) is trading 48.1% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 115 trading days ago — a "death cross", a bearish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 15, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 38, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 7 trading days ago (its momentum flipped negative). It just made a new 20-day low, its first since 2026-08-13, breaking below its recent trading range. It is 77.2% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 48.1% below its 200-day average, the long-term trend line — a long-term downtrend | -48.0% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $0.8112 | $0.8112 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $1.35 | $1.35 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 17 calendar days ago — the swings before that are what the structure reading is measured on | 17 sessions |
| Wave structure | its recent swings can be read as a completed three-part upward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes above 1.05. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave upward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 115 trading days ago — a "death cross", a bearish long-term signal | 115 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 15, below the 25 that marks a real trend) | 15.1 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 38, neither overbought (above 70) nor oversold (below 30) | 38.4 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($0.67 to $1.05) — its "stochastic" reading is 8 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 8.0 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 7 trading days ago (its momentum flipped negative) | 7 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $3.07 | $3.07 |
|---|---|---|
| From the 52-week high | it is 77.2% below its 52-week high (its highest price of the past year) | -77.2% |
| Above the 52-week low | it is 32.7% above its 52-week low (its lowest price of the past year) | +32.6% |
| Below the 52-week high | it is 77.2% below its highest point of the past year | 77.2% |
| Since a 20-day breakout | it just made a new 20-day low, its first since 2026-08-13, breaking below its recent trading range | 1 session |
| Since a 55-day breakout | it made a new 55-day high about 14 trading days ago | 14 sessions |
| All-time high | its highest closing price on record is $78.82 (set on 2021-11-30) | $78.82 |
| Given back of the 52-week move | over the past year its closes ranged ($0.535 to $2.88), and it has recovered only a small part of its fall from last year’s high — 7% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $1.98 to $2.06. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 7.0% |
| From the all-time high | it is 99.1% below its all-time high | -99.1% |
| Nearest price level | it is sitting right on a support level at $0.7001 — a price it turned at twice since 2025-05-23, most recently on 2025-07-07. Since 2024-10-08 it has 5 such levels below the current price and 7 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -0.0% |
| All-time low | its lowest closing price on record is $0.3547 (set on 2025-01-30) | $0.3547 |
| Above the all-time low | it is 97.5% above its all-time low | +97.5% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 33rd percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.0838 between its high and its low — about 12.0% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.0838 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $0.68 and $1.01 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $0.68 – $0.85 – $1.01 |
| Typical daily range (% of price) | its price moves about 12.0% in a typical session — among the most volatile in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 12.0% |
| Stretch from the 200-day average | it is trading 7.7 daily ranges below its 200-day average price (48.1% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 7.7 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.63× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
3
| Since a hammer | 4 sessions ago, after a stretch of decline, it sold off hard during the session and then closed back near its high — a "hammer", the long lower wick showing the drop was bought back before the close | 4 sessions ago |
|---|---|---|
| Since a bullish engulfing | 3 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 3 sessions ago |
| Since a bearish engulfing | 2 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 2 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-10-08 1.5% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +1.5% |
|---|---|---|
| Open gap | it gapped 3.1% below the previous close 7 sessions ago and has not traded back through the level it left behind at 0.95 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -3.0% |
| Gap filled | a 2.2% gap up opened on 2026-10-02 has been "filled" 4 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 4 sessions ago |
Price streaks
1
| Closing streak | it has closed lower 3 sessions in a row, a -16.52% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 3 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 16.2 percentage points (the stock lost 15.2% while the market gained 1.0%) | -16.3% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 19.4 percentage points (the stock lost 15.6% while the market gained 3.8%) | -19.4% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 63.6 percentage points (the stock lost 46.1% while the market gained 17.5%) | -63.6% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 72.3 percentage points (the stock lost 57.3% while the market gained 15.0%) | -72.3% |
Signal agreement
2
| Bullish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bullish state: near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 1 of 9 |
|---|---|---|
| Bearish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, a fresh 20-day low, MACD momentum is negative, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 11% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 8.0% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -11.2% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 40% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $1.17 — a volume-weighted average of daily closes over 188 sessions, not a true tick-by-tick VWAP. | -40.2% |
|---|---|---|
| Vs the average paid since it last reported | the price is 19% below the average price paid since it last reported on 2026-08-13 (its 10-Q), so the typical buyer over that stretch is under water. That average is $0.8676 — a volume-weighted average of daily closes over 40 sessions, not a true tick-by-tick VWAP. | -19.3% |
Double top, bearish — broke down · entry $0.746 · 33 sessions in
Rising wedge, bearish — broke down · entry $0.8291 · 77 sessions in
Price levels it has turned at before
IVVD last closed at $0.7004 on 2026-10-08. Since 2024-10-08 it has turned at 5 prices below its last close and 7 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $0.7001 | Support | at the last close | turned there twice · 2025-05-23 to 2025-07-07 |
| $0.6795 | Support | 3.0% below the last close | turned there twice · 2025-06-23 to 2025-07-31 |
| $0.729 | Resistance | 4.1% above the last close | turned there twice · 2026-06-12 to 2026-09-17 |
| $0.6615 | Support | 5.5% below the last close | turned there twice · 2025-07-16 to 2026-08-14 |
| $0.815 | Resistance | 16.4% above the last close | turned there twice · 2025-06-26 to 2025-08-11 |
| $1.01 | Resistance | 44.2% above the last close | turned there four times · 2026-05-20 to 2026-08-31 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part upward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $1.05.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
This reading has stood for 9 trading days, since 2026-09-28.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · Broke down to a new 20-day low · trendless / choppy (low ADX) · lagging the market · Most volatile (6%+ typical daily range) | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.00 mean, 1=Strong Buy…5=Strong Sell) — 3 analysts
- Mean price target$10.00 range $10.00 – $10.00
Analyst estimates, as of 2026-10-03. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for IVVD
- Consensus EPS estimate-$0.15 next reporting period, as of 2026-10-03
- Estimate change, 30 days$0.00 from -$0.15, on 2026-08-28, 36-day window
- Readings revised upward0% of 6 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Significant doubt regarding ability to continue as a going concern due to limited cash runway relative to operating expenses.","Dependence on a single authorized product, PEMGARDA, with its EUA set to expire on June 29, 2027.","Uncertainty regarding successful BLA approval for current and future product candidates to sustain revenue."]
What changed in the latest 10-Q
AI-assisted comparison of IVVD's 10-Q filed 2026-05-14 against the prior one filed 2025-11-06.
Management's Discussion & Analysis (MD&A)
- Added:
- Reference to 2025 Form 10-K filed March 5, 2026 (newer filing) vs. 2024 Form 10-K filed March 20, 2025 (older filing)
- New bullet point about REVOLUTION clinical program for VYD2311 and delivery through 'healthcare system- and patient-friendly means'
- New bullet point about commitment to developing 'robust pipeline' of product candidates
- New bullet point about expanding into RSV and measles as 'high-need indications'
- New bullet point about ability to identify and develop product candidates that 'exert continuous pharmaceutical activity in the face of viral evolution'
- New reference to SPEAR as '(Spike Protein Elimination and Recovery) Study Group' with added parenthetical definition
- Removed:
- Older bullet point stating PEMGARDA was 'designed to keep pace with SARS-CoV-2 viral evolution' (replaced with language about continuous pharmaceutical activity)
- Older bullet point about 'expectations regarding availability of a rapid pathway to potential Biologics License Application (BLA) approval for VYD2311'
- Older bullet point about 'compact pivotal clinical trial' for VYD2311
- Older bullet point referencing specific clinical trials 'DECLARATION and LIBERTY' as part of REVOLUTION program
- Older bullet point about 'aim to develop mAbs' (changed to 'commitment to developing')
- Older bullet point about 'discovery efforts to assess pipeline expansion beyond SARS-CoV-2'
- Older bullet point about 'goal of establishing streamlined development pathways'
- Older bullet point about ability to 'identify and develop future product candidates' (narrowed to remove 'future')
- Reworded:
- Overview sentence changed from 'devoted to delivering' to 'focused on the discovery, development and commercialization of monoclonal antibody therapies for the prevention and treatment' with additional detail
- PEMGARDA description changed from 'designed to keep pace with SARS-CoV-2 viral evolution' to 'designed to exert continuous pharmaceutical activity in the face of viral evolution'
- VYD2311 language changed from 'system- and patient-friendly means' to 'healthcare system- and patient-friendly means' (added 'healthcare')
- Language changed from 'our aim to develop mAbs' to 'our commitment to developing a robust pipeline of product candidates'
- Language changed from 'potentially expanding into other high-need indications' to definitive expansion language with specific mention of RSV and measles
- Removed mention of 'expectations regarding' and 'future product candidates' in favor of present-focused language on continuous pharmaceutical activity capability
- Notes:
- Text is truncated at end of Overview section in both filings; comparison limited to provided excerpts
- Changes reflect updates to forward-looking statements between Q3 2025 filing (Sept 30, 2025 quarter end) and Q1 2026 filing (March 31, 2026 quarter end)
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 10 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 90 days · read to 2026-10-040 buys · 10 sells ($177089) — 5 selling insiders
- Last 180 days · read to 2026-10-040 buys · 10 sells ($177089) — 5 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-18. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about IVVD's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding IVVD as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 28,286,338
- Reported value $24,677,001
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 4 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about IVVD's institutional holders → See what each manager we track holds →
Short interest (FINRA)
IVVD had 30,556,394 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
IVVD had 10.4% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 7.7 days to cover at the same settlement.
- Reported short interest (shares) 30,556,394
- Short interest (% of shares outstanding) 10.4%
- Prior settlement (shares) 29,787,846
- Reported change 2.58%
- Days to cover (reported) 7.7
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- AstraZeneca (AZN)
- Gilead Sciences (GILD)
- Sanofi (SNY)
- GSK (GSK)
- Moderna (MRNA)
- Pfizer (PFE)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare IVVD vs…
Frequently asked questions
What does INVIVYD INC (IVVD) do?
Invivyd is a biopharmaceutical company focused on the discovery, development, and commercialization of monoclonal antibody (mAb) therapies for the prevention and treatment of serious viral infectious diseases. Its primary focus is on SARS-CoV-2 (COVID-19), with its authorized product PEMGARDA being used for pre-exposure prophylaxis in immunocompromised individuals.
What sector is INVIVYD INC (IVVD) in?
INVIVYD INC (IVVD) is classified in the Health Care sector. Its industry is Biotechnology. It trades on NASDAQ.
Who are INVIVYD INC's (IVVD) competitors?
Notable peers of INVIVYD INC (IVVD) include AstraZeneca, Gilead Sciences, Sanofi, GSK and Moderna. This peer set is informational only — not financial advice.
Is INVIVYD INC (IVVD) overbought or oversold right now?
INVIVYD INC (IVVD) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 38, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on IVVD come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.